BENGALURU (Reuters) – Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.
The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an emailed statement.
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Krishna Chandra Eluri)
